PERTH, Australia – Roughly 40% of Australia’s biotech companies are seeking capital as they feel the pinch from international travel bans that seriously hamper capital raising, according to a recent Ausbiotech survey.

Biopharmas in Asia-Pacific raising money in public or private financings, including: Pluristem.

Med-tech firms raising money in public or private financings, including: Defymed, Embody, Pulmonx.

Biopharmas raising money in public or private financings, including: Bergenbio, Fennec, Insmed, Kineta, Lyra, Motif, Oberland, Pluristem, Portage, Saugatuck.

Med-tech firms raising money in public or private financings, including: Titan Medical.

Biopharmas raising money in public or private financings, including: Avadel, Ayala, Clarametyx, Devonian Health, Immunomedics, Intec.

Med-tech firms raising money in public or private financings, including: Pulse Biosciences, Second Sight Medical Products.

9 Meters Biopharma Inc., of Raleigh, N.C., is newly born from the merger of Innovate Biopharmaceuticals Inc. and privately held RDD Pharma Ltd., of New York and Tel Aviv, Israel. About $22 million in new financing, led by Orbimed Advisors Ltd., and the signing of another merger into the new company of Richmond, Calif.-based Naia Rare Diseases Inc., which develops GLP-1 to treat short bowel syndrome, completes 9 Meters’ new path.

Biopharmas raising money in public or private financings, including: Acer, Achieve, Aeglea, Algernon, Alume, IMV, Lyra, Neubase.